TCW Group’s Regeneron Pharmaceuticals REGN Stock Holding History

TCW Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Sell	1,665 -374	-18%	-$286K	0.01%	327
2025 Q4	$1.57M	Buy	+2,039	New	+$1.38M	0.01%	304
2015 Q2	–	Sell	-21,450	Closed	-$9.68M	–	708
2015 Q1	$9.68M	Buy	21,450 +650	+3%	+$275K	0.05%	255
2014 Q4	$8.53M	Sell	20,800 -15,350	-42%	-$6.04M	0.04%	296
2014 Q3	$13M	Sell	36,150 -3,850	-10%	-$1.29M	0.05%	275
2014 Q2	$11.3M	Buy	40,000 +850	+2%	+$252K	0.05%	313
2014 Q1	$11.8M	Buy	39,150 +300	+0.8%	+$92.4K	0.05%	299
2013 Q4	$10.7M	Buy	38,850 +350	+0.9%	+$101K	0.05%	319
2013 Q3	$12M	Buy	38,500 +1,050	+3%	+$276K	0.06%	274
2013 Q2	$8.42M	Buy	+37,450	New	+$8.72M	0.04%	339

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TCW Group's REGN Position: Q1 2026 in Review

TCW Group reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $286K and leaving 1,665 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #327.

TCW Group first reported a position in REGN in Q2 2013 and has held it in 10 quarters since. The position peaked at $13M in Q3 2014. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

TCW Group held 1,665 shares of Regeneron Pharmaceuticals worth $1.29M as of Q1 2026.
TCW Group sold 374 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $286K.
Regeneron Pharmaceuticals made up 0.01% of TCW Group's portfolio in Q1 2026, its #327 holding.
TCW Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 10 quarters since.
TCW Group's Regeneron Pharmaceuticals position peaked at $13M in Q3 2014.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on TCW Group's 13F filing for Q1 2026, filed 14 May 2026.